Psychedelic research continues to accelerate, and one of the most exciting developments is our growing understanding of the cellular mechanism of psilocin, the active compound produced when the body metabolizes psilocybin. A recent study published in Molecular Psychiatry offers one of the most detailed looks yet at how psilocin interacts with individual brain cells in the medial prefrontal cortex, a region involved in mood regulation, cognitive flexibility, and decision making.
Scientists have known for years that psilocybin and psilocin act on the serotonin 5 HT2A receptor. What has been less clear is which specific neurons respond, how their electrical activity changes, and what internal signaling pathways drive these effects. This new research helps piece together that puzzle.
How Psilocin Activates Specific Neurons In The Prefrontal Cortex
Using a combination of functional MRI and electrophysiological recordings in mice, researchers tracked how psilocin influences brain activity across different levels. Their first step was to measure whole brain activity after giving psilocin. The scans showed striking increases in activity within the medial prefrontal cortex, especially in regions similar to the prelimbic and anterior cingulate areas. These areas play important roles in emotional processing and are often disrupted in depression and anxiety.
To understand which neurons were responsible, the team recorded electrical activity from individual cells. When they looked at a general population of neurons, the effects were mixed. Some cells became more active, others quieted down, and some showed no change. This variation suggested that psilocin acts on very specific cell types rather than the entire region at once.
The key insight came from using genetically engineered mice whose 5 HT2A receptor containing neurons glowed under fluorescent light. Once scientists were able to identify these cells directly, the results became clear. When exposed to psilocin, these neurons consistently doubled their firing rate and became easier to excite with electrical input. This suggests that psilocin directly increases the excitability of these specific neurons, rather than altering the signals they receive from their neighbors.
The Receptor And Signaling Pathway Behind The Effect
To confirm the mechanism, researchers tested whether activating or blocking certain receptors changed the response. A compound that activates only the 5 HT2A receptor reproduced the effects of psilocin. A drug that blocks that same receptor prevented psilocin from increasing neuron firing. Blocking a related receptor, the 5 HT2C receptor, had no impact, meaning it does not contribute to this direct excitatory effect.
The final step was identifying the internal signaling pathway. The 5 HT2A receptor typically signals through a protein called Gαq. When scientists used a compound that inhibits Gαq, psilocin no longer increased neuronal firing. This means that the cellular mechanism of psilocin relies on activating 5 HT2A neurons through the Gαq pathway.
Why These Findings Matter for Mental Health Treatment
Understanding how psilocin excites specific neurons is more than a scientific milestone. It offers clues about how psychedelic assisted therapy may help treat conditions like depression and anxiety. The prefrontal cortex is central to mood regulation, problem solving, and cognitive control. If psilocin reliably enhances activity in targeted neurons within this region, it could help explain its potential therapeutic effects.
The study also highlights that these cellular changes occur independently of complex network interactions, suggesting that some therapeutic benefits may arise from direct actions on specific neurons rather than broadly altering entire circuits.
Researchers caution that these findings are based on animal models, which do not always translate perfectly to humans. Still, this work lays important groundwork for understanding how psychedelics influence brain function at the most fundamental level.
Citations
1. Schmitz G. P., Chiu Y.-T., Foglesong M. L., et al. “Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation.” Translational Psychiatry (2025). https://pubmed.ncbi.nlm.nih.gov/41052972/
2. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience. https://doi.org/10.1038/s41583-020-0367-2